We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder

By LabMedica International staff writers
Posted on 28 Mar 2025

Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or blood cancer. More...

Although the exact cause of CCUS remains unclear, studies have shown that it can often progress into blood cancer. Patients with CCUS are at a tenfold increased risk of developing conditions such as myelodysplastic syndromes or acute myeloid leukemia. Now, researchers have developed a new method to predict the likelihood of cancer development in individuals with CCUS.

An international team of researchers led by Northwestern University (Evanston, IL, USA) conducted a study involving over 350 patients with CCUS. By analyzing the genetic mutations, low blood counts, and corresponding outcomes, the scientists created a scoring system aimed at better risk stratification and predicting the potential for blood cancer development. The team then validated their model with a separate group of 100 CCUS patients, finding that it accurately predicted the risk of blood cancer. The results, published in the journal Blood, demonstrate that this risk scoring system can help identify which patients are most likely to develop cancer, potentially allowing for early intervention in the future. Going forward, the researchers plan to integrate this scoring system into future clinical trials for CCUS patients.

“The take-home message from this is that there are three major predictors of outcomes in these patients,” said Yasmin Abaza, MD, assistant professor of Medicine in the Division of Hematology and Oncology, who was a co-author of the study. “If you have particular mutations, we call them splicing factor mutations, which are one of the major weights in determining prognosis. Also, if you have a platelet count of less than 100. The third is having two or more genetic mutations.”

“This scoring system has not been adopted yet, but hopefully as we have more patients and further validate and compare it to other scoring systems, later on it could be implemented clinically,” Abaza added.


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Respiratory Infections Test
STANDARD Q Adeno Respi Ag Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.